Skip to Content


Active Substance: fomivirsen
Common Name: fomivirsen
ATC Code: S01AD08
Marketing Authorisation Holder: Novartis Ophthalmics Europe Ltd.
Active Substance: fomivirsen
Status: Withdrawn
Authorisation Date: 1999-07-29
Therapeutic Area: Cytomegalovirus Retinitis HIV Infections
Pharmacotherapeutic Group: Ophthalmologicals

Therapeutic Indication

For the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immuno-deficiency syndrome (AIDS).
Until further experience is gained, fomivirsen should be used only when other therapy has been ineffective or is considered unsuitable.

The marketing authorisation for Vitravene has been withdrawn at the request of the marketing authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.